首页> 外文OA文献 >Impact of Recombinant Adenovirus Serotype 35 Priming versus Boosting of a Plasmodium falciparum Protein: Characterization of T- and B-Cell Responses to Liver-Stage Antigen 1▿
【2h】

Impact of Recombinant Adenovirus Serotype 35 Priming versus Boosting of a Plasmodium falciparum Protein: Characterization of T- and B-Cell Responses to Liver-Stage Antigen 1▿

机译:重组腺病毒血清型35启动与恶性疟原虫蛋白质增强的影响:对肝阶段抗原1的T细胞和B细胞反应的表征

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Prime-boost vaccination regimens with heterologous antigen delivery systems have indicated that redirection of the immune response is feasible. We showed earlier that T-cell responses to circumsporozoite (CS) protein improved significantly when the protein is primed with recombinant adenovirus serotype 35 coding for CS (rAd35.CS). The current study was designed to answer the question whether such an effect can be extended to liver-stage antigens (LSA) of Plasmodium falciparum such as LSA-1. Studies with mice have demonstrated that the LSA-1 protein induces strong antibody response but a weak T-cell immunity. We first identified T-cell epitopes in LSA-1 by use of intracellular gamma interferon (IFN-γ) staining and confirmed these epitopes by means of enzyme-linked immunospot assay and pentamer staining. We show that a single immunization with rAd35.LSA-1 induced a strong antigen-specific IFN-γ CD8+ T-cell response but no measurable antibody response. In contrast, vaccinations with the adjuvanted recombinant LSA-1 protein induced remarkably low cellular responses but strong antibody responses. Finally, both priming and boosting of the adjuvanted protein by rAd35 resulted in enhanced T-cell responses without impairing the level of antibody responses induced by the protein immunizations alone. Furthermore, the incorporation of rAd35 in the vaccination schedule led to a skewing of LSA-1-specific antibody responses toward a Th1-type immune response. Our results show the ability of rAd35 to induce potent T-cell immunity in combination with protein in a prime-boost schedule without impairing the B-cell response.
机译:具有异源抗原递送系统的初免-加强疫苗接种方案表明免疫应答的重定向是可行的。我们先前显示,当用编码CS的重组腺病毒血清型35(rAd35.CS)引发该蛋白时,对环子孢子(CS)蛋白的T细胞反应显着改善。当前的研究旨在回答以下问题:是否可以将这种作用扩展到恶性疟原虫的肝阶段抗原(LSA),例如LSA-1。小鼠研究表明,LSA-1蛋白可诱导强抗体反应,但T细胞免疫力较弱。我们首先通过细胞内γ干扰素(IFN-γ)染色在LSA-1中鉴定了T细胞表位,并通过酶联免疫斑点测定和五聚体染色证实了这些表位。我们显示,用rAd35.LSA-1进行的单次免疫诱导了强抗原特异性IFN-γCD8 + T细胞应答,但没有可测量的抗体应答。相反,用佐剂的重组LSA-1蛋白进行疫苗接种可诱导出明显的低细胞反应,但抗体反应却很强。最后,rAd35对佐剂蛋白的引发和增强作用均导致增强的T细胞应答,而不会损害仅由蛋白免疫诱导的抗体应答的水平。此外,在疫苗接种时间表中掺入rAd35导致LSA-1特异性抗体反应向Th1型免疫反应倾斜。我们的结果表明,rAd35能够在初免-加强程序中与蛋白质结合诱导有效的T细胞免疫,而不会损害B细胞反应。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号